Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)

Authors
Publication date
4 March 2021
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    İstanbul Üniversitesi Açık Erişim Sistemi

    redirect
    oaioai:http://acikerisim.istanbul...
    Last time updated on 19/10/2022